Announcements

August 16, 2018 – Spasticity-related pain reduction and quality of life improvements seen in patients with post-stroke severe spasticity

January 11,2018 – New level 1 evidence for post-stroke severe spasticity

September 1, 2017 – Saol Therapeutics acquires three hyperimmune products from Aptevo Therapeutics

June 30, 2017 – Saol Therapeutics signs co-promotion agreement with Ipsen Biopharmaceuticals for Dysport® (abobotulinumtoxinA)

January 15, 2016 – Saol Therapeutics acquires Lioresal® Intrathecal (baclofen injection)

 

 

 

 

 

For full prescribing information of Lioresal® Intrathecal (baclofen injection), including BOX WARNING, please click here.

For full prescribing information of Dysport®, including BOX WARNING, please click here.

 

DYSPORT is a registered trademark of Ipsen Biopharm Limited.